Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 16, Issue 12, Pages 773-778Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41571-019-0262-9
Keywords
-
Categories
Funding
- Joan and Irwin Jacobs Fund
- NIH P30 grant [CA023100]
Ask authors/readers for more resources
For many years, oncology phase I trials have been referred to as 'toxicity trials' and have been believed to have low clinical utility other than that of establishing the adverse event profile of novel therapeutic agents. The traditional distinction of clinical trials into three phases has been challenged in the past few years by the introduction of targeted therapies and immunotherapies into the routine management of patients with cancer. This transformation has especially affected early phase trials, leading to the current situation in which response rates are increasingly reported from phase I trials. In this Perspectives, we highlight key elements of phase I trials and discuss how each one of them contributes to a new paradigm whereby preliminary measurements of the clinical benefit from a novel treatment can be obtained in current phase I trials, which can therefore be considered to have a therapeutic intent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available